Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Successful elimination of large established tumors and avoidance of antigen-loss variants by aggressive adoptive T cell immunotherapy.

International immunology - 1 Jul 2003

Matsui Ken, O'Mara Leigh A, Allen Paul M

Abstract excerpt

Utilization of ex vivo-expanded epitope-specific cytotoxic T lymphocytes has become a clinical standard in the adoptive immunotherapy of tumors. One of the obstacles faced by T cell-based immunotherapy is the development of tumor immune-escape variants. Using our previously reported CMS5 tumor/DUC18 CD8(+) TCR transgenic system, we sought to investigate whether large established tumors can be successfully...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antigenic Variation
Share to Antigens, Neoplasm
Share to Epitopes

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Epitopes, T-Lymphocyte

Share to Immunotherapy, Adoptive

Share to Lymphocyte Activation

Share to Neoplasms, Experimental

Share to T-Lymphocytes, Cytotoxic

Source

Identifiers

PMID: 12807818
DOI: 10.1093/intimm/dxg078

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Successful elimination of large established tumors and avoidance of antigen-loss variants by aggressive adoptive T cell immunotherapy.PMID 12807818Read ↗

Eradication of established tumors by CD8+ T cell adoptive immunotherapy.Semantic proximity Read ↗

An effective mouse model for adoptive cancer immunotherapy targeting neoantigensSemantic proximity Read ↗

Tracking the common ancestry of antigenically distinct cancer variants.Semantic proximity Read ↗

Adoptive T cell therapy promotes the emergence of genomically altered tumor escape variantsSemantic proximity Read ↗

Selective cytotoxic T-lymphocyte targeting of tumor immune escape variants.Semantic proximity Read ↗

Altered MHC class I antigens in tumors.Semantic proximity Read ↗

Tissue homing and persistence of defined antigen-specific CD8+ tumor-reactive T-cell clones in long-term melanoma survivors.Semantic proximity Read ↗

Fas expression by tumor stroma is required for cancer eradicationSemantic proximity Read ↗

Cutting edge: permissive MHC class II allele changes the pattern of antitumor immune response resulting in failure of tumor rejection.Semantic proximity Read ↗

Characteristics and in vivo homing of long-term T-cell lines and clones derived from tumor-draining lymph nodes.Semantic proximity Read ↗

Analysis of a natural immune response against tumor antigens in a melanoma survivor: lessons applicable to clinical trial evaluations.Semantic proximity Read ↗

Modeling the specific CD4+ T cell response against a tumor neoantigen.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.